[et_pb_section bb_built=”1″ admin_label=”section” background_color=”#19459c”][et_pb_row admin_label=”row”][et_pb_column type=”4_4″][et_pb_text admin_label=”Text” background_layout=”dark” text_orientation=”center” text_font=”Cardo||||”]

BENIGN PROSTATIC HYPERPLASIA

Open Trials

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section bb_built=”1″ admin_label=”section”][et_pb_row admin_label=”row”][et_pb_column type=”1_4″][/et_pb_column][et_pb_column type=”3_4″][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]

BPH Study Medi-Tate Protocol MT-03  

A phase II study, randomized, controlled multi-center evaluation of the safety and effectiveness of Medi-Tate temporary implantable Nitinol Device (iTIND) in subjects with symptomatic benign prostatic hyperplasia (BPH).

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section bb_built=”1″ admin_label=”section”][et_pb_row admin_label=”row”][et_pb_column type=”4_4″][et_pb_text admin_label=”Text” text_orientation=”right”]

If you would like to learn more information about our current clinical study listed above, please contact 516-931-0041.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section bb_built=”1″ admin_label=”section” background_color=”#000000″][/et_pb_section]